$BIIB
Price history, market instrument context, member research, and related headlines in one place.
BIIB key statistics
NasdaqGSUSD
52-week range
$138.0095%$240.99
Latest session $235.22–$240.99Biogen Inc. (BIIB) is a stock instrument quoted on NasdaqGS in USD. The most recently published price is $235.35, up $2.52 (1.08%) from the previous close of $232.83. It has traded between $235.22 and $240.99 in the latest session. Over the past year it has ranged from $138.00 to $240.99, leaving it in the upper quarter of its 52-week range (95%). Reported volume for the session was 1.6M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Biogen stock price target raised to $251 by H.C. Wainwright — See source for full details.
Biogen outlines 2026 non-GAAP EPS $12-$13 and expects SYFOVRE and EMPAVELI mid- to high teens growth through at least 2028 — See source for full details.
Earnings call transcript: Biogen beats Q2 2026 estimates, lifts revenue outlook — See source for full details.
Biogen beats top-line and bottom-line estimates; updates FY26 outlook — See source for full details.
July 29 () - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure. Investors are closely watching whether recent deals and newer products including its Alzheimer
Loading $BIIB research…